Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;2(1):25-37.
doi: 10.1177/1758834009356014.

Targeted therapies in small cell lung cancer: a review

Aidalena Z Abidin  1 , Marina C Garassino, Raffaele Califano, Amelie Harle, Fiona Blackhall
Affiliations

Targeted therapies in small cell lung cancer: a review

Aidalena Z Abidin et al. Ther Adv Med Oncol. 2010 Jan.

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.

Keywords: BH3 mimetics; MET inhibitors; angiogenesis inhibitors; apoptosis promoters; cell signalling inhibitors; multidrug resistance inhibitors; small cell lung cancer (SCLC); targeted therapies; vaccines.

PubMed Disclaimer

References

    1. Antonia S.J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., et al. (2006) Combination of P53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878–887 - PubMed
    1. Arnold A.M., Seymour L., Smylie M., Ding K., Ung Y., Findlay B., et al. (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study Br.20. J Clin Oncol 25: 4278–4284 - PubMed
    1. Besse, B., Suk Heist, R., Papadimitrakopoulou, V., Camidge, D., Beck, J.T., Schmid, P. et al. (2009) Phase I dose-escalation study investigating Rad001 (R) in combination with cisplatin (C) and etoposide (E) in previously untreated patients with extensive-stage disease small-cell lung cancer (ED-SCLC), 13th World Conference on Lung Cancer. San Francisco, California, USA.
    1. Blackhall F.H., Shepherd F.A. (2004) Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. Hematol Oncol Clin North Am 18: 1121–1141, ix - PubMed
    1. Blackhall F.H., Pintilie M., Michael M., Leighl N., Feld R., Tsao M.S., et al. (2003) Expression and prognostic significance of kit, protein kinase b, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241–2247 - PubMed

LinkOut - more resources